When was Clock.bio founded?

Clock.bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Clock.bio located?

Clock.bio is headquartered in Cambridge, United Kingdom. It is registered at PIONEER HOUSE VISION PARK,HISTON,CAMBRIDGE,CAMBRIDGESHIRE,UNITED KINGDOM,CB24 9NL.

Which legal entities is Clock.bio associated with?

Clock.bio is associated with CLOCK BIO LIMITED.

Is Clock.bio a funded company?

Clock.bio is a funded company, having raised a total of $9.93M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 29, 2021.

How much is Clock.bio worth?

The latest valuation of Clock.bio is £***** as of Apr 30, 2024.

When was the latest funding round of Clock.bio?

Clock.bio's latest funding was a $***** Seed round on Apr 30, 2024, with participation from 4 investors. Its primary sector is Regenerative Medicine. Globally, the Regenerative Medicine sector has seen $67.3M in funding in 2026 to date.

Where does Clock.bio rank among its competitors?

Clock.bio ranks 23rd amongst 290 active competitors, of which 83 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Stellular Bio, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of Clock.bio?

Clock.bio's top competitors include Revance Therapeutics, Evolus and Aspen Neuroscience. Among them, Stellular Bio secured the most recent funding round in January, 2026.

Clock.bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Clock.bio is a seed company based in Cambridge (United Kingdom), founded in 2020 by Koby Baranes and Joana Tavares. It operates as a Developer of treatments for age-related diseases using human pluripotent stem cells. Clock.bio has raised $9.93M in funding from LocalGlobe, with a current valuation of £*****. The company has 290 active competitors, including 83 funded and 79 that have exited. Its top competitors include companies like Revance Therapeutics, Evolus and Aspen Neuroscience.

Company Details

Developer of treatments for age-related diseases using human pluripotent stem cells. This company harnesses the regenerative capabilities of these cells to identify and develop novel therapies. They utilize a unique aging model to force-age induced pluripotent stem cells (iPSCs), triggering their self-rejuvenation mechanism. Unbiased CRISPR screens then identify genes crucial for cell rejuvenation, enabling a comprehensive understanding of rejuvenation biology and the creation of new treatment approaches. The technology allows for rapid decoding of human rejuvenation biology, accelerating the development of effective therapies.

Website: clock.bio
Email ID: *****@clock.bio
Registered Address: PIONEER HOUSE VISION PARK,HISTON,CAMBRIDGE,CAMBRIDGESHIRE,UNITED KINGDOM,CB24 9NL

Key Metrics

Founded Year

2020

Location

Cambridge, United Kingdom

Stage

Seed

Total Funding

$9.93M in 3 rounds

Latest Funding Round

Seed, Apr 30, 2024, $*****

Post Money Valuation

£***** as on Apr 30, 2024

Investors

LocalGlobe & 7 more

Ranked

23^rd among 290 active competitors

Similar Companies

Revance Therapeutics & 365 more

View Clock.bio's full profile

Clock.bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CLOCK BIO LIMITED CIN: 12909273 , United Kingdom, Active	Sep 27, 2020	-	5 (As on Dec 31, 2024)

Clock.bio has raised a total funding of $9.93M over 3 rounds. Its first funding round was on Dec 29, 2021. Its latest funding round was a Seed round on Apr 30, 2024 for $*****. 4 investors participated in its latest round. Clock.bio has 7 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Clock.bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2024	2670011	Seed	4055566	2142020	7063627	5751879
Feb 29, 2024	9688561	Seed	7482324	4656202	5038365	8120020
Dec 29, 2021	5982870	Seed	9856582	9231421	6051286	8942835

Access funding benchmarks and valuations. Sign up today!

View details of Clock.bio's funding rounds and investors

The founders of Clock.bio are Koby Baranes and Joana Tavares. Markus Gstottner is the CEO of Clock.bio.

Here are the details of Clock.bio's key team members:

Koby Baranes: Co-Founder of Clock.bio.
Joana Tavares: Co-Founder of Clock.bio.
Markus Gstottner: CEO of Clock.bio.

View details of Clock.bio's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Clock.bio include Revance Therapeutics, Evolus and Aspen Neuroscience. Here is the list of Top 10 competitors of Clock.bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	72/100
2nd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	68/100
3rd	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	65/100
4th	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$50.5M	Indian Angel Network, BTB Venture & 86 others	65/100
5th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
6th	Avita Medical 1992, Cambridge (United Kingdom), Public	Regenerative and Respiratory Medicine product company	-	NorthStar Impact, BioScience Managers & 6 others	62/100
7th	Dermavant 2016, Phoenix (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases	$160M	Marathon Asset Management, NovaQuest Capital Management ... Read more	61/100
8th	Clinuvel 2001, Melbourne (Australia), Public	Biopharma company focused on developing drugs for skin disorders	$51M	-	61/100
9th	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Vivo Capital, Qiming & 5 others	61/100
10th	Orthofix 1980, Lewisville (United States), Public	Developer of reconstructive and regenerative solutions for bone-related conditions	-	-	60/100
23rd	Clock.bio 2020, Cambridge (United Kingdom), Seed	Developer of treatments for age-related diseases using human pluripotent stem cells	$9.93M	LocalGlobe, Firstminute Capital & 6 others	55/100